Human immunodeficiency virus type 1 (HIV-1) (HIV-1)

Human immunodeficiency virus type 1 (HIV-1) is the primary causative agent of Acquired Immunodeficiency Syndrome (AIDS), a condition characterized by the progressive failure of the immune system and susceptibility to opportunistic infections (NIH, 2023). The term "HIV-1 entry/replication in MAGI cells" refers to a phenotypic assay rather than a specific molecular target. MAGI (Multinuclear Activation of a Galactosidase Indicator) cells are a modified HeLa cell line engineered to express CD4 and coreceptors (CXCR4/CCR5), containing an integrated HIV-1 LTR-driven reporter gene that activates upon successful infection (Kimpton & Emerman, 1992). This assay is widely used in drug discovery to identify compounds that inhibit various stages of the viral life cycle, including attachment, fusion, and early replication. Current therapeutic strategies involve Highly Active Antiretroviral Therapy (HAART), which utilizes combinations of drugs such as entry inhibitors, reverse transcriptase inhibitors, and integrase inhibitors to suppress viral load (PubChem, 2024). Despite the success of these treatments, challenges remain, including the development of multi-drug resistance and the inability to eliminate latent viral reservoirs (WHO, 2023).

Other names

HIV-1 entry/replicationMAGI assayHIV-1 infectionHuman immunodeficiency virus 1

Inhibition of viral entry (fusion or coreceptor binding), reverse transcription, integration, or proteolytic maturation.